<DOC>
	<DOCNO>NCT00500422</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose drug Velcade ( bortezomib ) give together gemcitabine pegylated liposomal doxorubicin ( Doxil ) treatment advanced cancer . The effect combination treatment tumor growth also study .</brief_summary>
	<brief_title>Doxil , Gemcitabine , Velcade ( PS341 ) Advanced Cancer Patients</brief_title>
	<detailed_description>Pegylated liposomal doxorubicin newer form common anticancer drug Adriamycin . It enclose liposome , fat particle find normally body . This new form design act cancer cell cause less damage normal tissue . Gemcitabine drug show active patient several different cancer include pancreatic cancer , breast cancer , certain lymphoma . Bortezomib new drug design block protein need tumor growth . Groups 3 participant less 65 year old 3-6 participant least 65 year old enrol time . Each new group receive high dose level group long serious side effect occur . Once high tolerable dose determine , 30 additional patient small cell cancer neuroendocrine carcinoma , 30 patient T cell lymphoma treat dose . All participant receive pegylated liposomal doxorubicin vein 2 hour . The drug give every 21 day ( 3 week 1 cycle ) . Gemcitabine give vein 30 minute Days 1 8 every 21 day . Patients receive combination drug Day 1 ; day pegylated liposomal doxorubicin give dose gemcitabine . Bortezomib give vein Days 1 , 4 , 8 11 every 21 day , except first group patient receive day 1 8 . Participants whose tumor respond treatment may continue treatment doctor approve long respond , long serious side effect . Because nationwide shortage pegylated liposomal doxorubicin , may continue treatment gemcitabine bortezomib . If pegylated liposomal doxorubicin become available , may able receive . During study , weekly blood test ( 2 tablespoon blood ) physical exam . X-rays scan , MRIs CT scan , do 6 week measure size tumor . Other test do need . The treatment stop cancer grows severe side effect occur , treatment may offer . This investigational study . All three drug approve FDA use kinds cancer . Their use study investigational . Up 276 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . All patient histologic proof advanced cancer , candidate know regimen protocol treatment higher efficacy priority therapy increase survival least 3 month , shall eligible study unless standard therapy include one drug protocol . 2 . Estimated life expectancy least 12 week . ( Performance status less equal 2 ( Zubrod scale ) . 3 . Patients must voluntarily sign informed consent indicate aware investigational nature study keep policy hospital . The acceptable consent form one attached end protocol . 4 . Evaluable disease 5 . Patients must previous chemotherapy radiotherapy least 3 week target biologic therapy least 5 halflives , whichever short , prior enter study . Patients may receive localized palliative radiotherapy immediately treatment . 6 . Adequate bone marrow function ( Absolute neutrophil count ( ANC ) &gt; 1,500 Platelet &gt; 100,000 ) except posttransplant arm hematologic minimum requirement apply disease infiltration bone marrow . 7 . Adequate liver function ( bilirubin less equal 1.5 mg % , alanine aminotransferase ( SGPT ) &lt; 5 time normal ) 8 . Adequate renal function ( creatinine less equal 1.5 mg % ) . 9 . Cardiac ejection fraction great equal 50 % without evidence Congestive heart failure ( CHF ) 10 . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . 11 . Male subject agree use acceptable method contraception duration study . 1 . Symptomatic brain metastasis require concurrent treatment , inclusive limit , surgery , radiation cortico steroid . 2 . Need concurrent radiotherapy chemotherapy ( localized palliative radiotherapy ) 3 . New York Heart Association Class &gt; II 4 . Diagnosis leukemia myelodysplastic syndrome 5 . Prior cumulative doxorubicin dose &gt; 300 mg/m^2 . Total cumulative dose doxorubicin plus Doxil exceed 550 mg/m^2 ( 400 mg/m ) 6 . Pregnant lactating woman . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . 7 . Patient great equal Grade 2 peripheral neuropathy within 14 day enrollment 8 . Concurrent uncontrolled infection require intravenous antibiotic 9 . Patient hypersensitivity bortezomib , boron , mannitol , doxorubicin , gemcitabine . 10 . Patient receive investigational drug within 14 day enrollment . 11 . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Doxil</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Pegylated Liposomal Doxorubicin</keyword>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>PS341</keyword>
	<keyword>PS-341</keyword>
	<keyword>LDP-341</keyword>
	<keyword>MLN341</keyword>
</DOC>